{
  "watchlist_rows": [
    {
      "company": "Pfizer",
      "total_score": 8.1,
      "fit_score": 2.0,
      "urgency_score": 3.0,
      "access_score": 2.0,
      "trigger_summary": "trial_candidate: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06215118",
        "https://clinicaltrials.gov/study/NCT06152575",
        "https://clinicaltrials.gov/study/NCT05020236",
        "https://clinicaltrials.gov/study/NCT06057402",
        "https://clinicaltrials.gov/study/NCT05090566",
        "https://clinicaltrials.gov/study/NCT04649359"
      ],
      "target_roles": [
        "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
        "Director/VP, Translational Medicine (Oncology/Immunology)",
        "Head/Director, Clinical Biomarkers / Translational Biomarkers",
        "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
        "Director, Bioassay / Potency / Analytical Development"
      ],
      "trial_count": 6,
      "recent_job_hits": 0,
      "best_fit_trial_title": "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)",
      "best_fit_trial_status": "RECRUITING",
      "best_fit_trial_phases": [
        "PHASE3"
      ],
      "best_fit_trial_last_update": "2026-02-03",
      "fit_reason": "trial title contains CD3",
      "urgency_reason": "trial status RECRUITING and phase in ['PHASE1']",
      "urgency_source": "trial",
      "access_reason": "company on watchlist / ATS known",
      "bonus_recent_trial": 0.5,
      "bonus_multi_trial": 0.6,
      "job_hit_titles": [],
      "job_hit_keywords": [],
      "score_details": {
        "trial_count": 6,
        "best_fit_trial": {
          "nct_id": "NCT06152575",
          "brief_title": "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)",
          "overall_status": "RECRUITING",
          "phases": [
            "PHASE3"
          ],
          "last_update_posted": "2026-02-03"
        },
        "best_urgency_trial": {
          "nct_id": "NCT06215118",
          "brief_title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
          "overall_status": "RECRUITING",
          "phases": [
            "PHASE1"
          ],
          "last_update_posted": "2026-02-05"
        },
        "jobs": {
          "recent_window_days": 45,
          "spike_threshold": 2,
          "relevant_recent_jobs": 0
        },
        "reasons": {
          "fit_reason": "trial title contains CD3",
          "urgency_reason": "trial status RECRUITING and phase in ['PHASE1']",
          "urgency_source": "trial",
          "access_reason": "company on watchlist / ATS known"
        },
        "bonuses": {
          "recent_trial_bonus": 0.5,
          "multi_trial_bonus": 0.6,
          "any_recent_trial_update": true
        },
        "weights": {
          "fit": 1.0,
          "urgency": 1.0,
          "access": 1.0
        }
      }
    },
    {
      "company": "AstraZeneca",
      "total_score": 7.1,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 2.0,
      "trigger_summary": "trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | trial_candidate: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06542250",
        "https://clinicaltrials.gov/study/NCT06564038",
        "https://clinicaltrials.gov/study/NCT05877599",
        "https://clinicaltrials.gov/study/NCT06218914",
        "https://clinicaltrials.gov/study/NCT06005493",
        "https://clinicaltrials.gov/study/NCT07215585",
        "https://clinicaltrials.gov/study/NCT07201558"
      ],
      "target_roles": [
        "Director/VP, Translational Medicine (Oncology/Immunology)",
        "Head/Director, Clinical Biomarkers / Translational Biomarkers",
        "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
        "Director, Bioassay / Potency / Analytical Development",
        "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
      ],
      "trial_count": 7,
      "recent_job_hits": 0,
      "best_fit_trial_title": null,
      "best_fit_trial_status": null,
      "best_fit_trial_phases": null,
      "best_fit_trial_last_update": null,
      "fit_reason": "no trials",
      "urgency_reason": "trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",
      "urgency_source": "trial",
      "access_reason": "company on watchlist / ATS known",
      "bonus_recent_trial": 0.5,
      "bonus_multi_trial": 0.6,
      "job_hit_titles": [],
      "job_hit_keywords": [],
      "score_details": {
        "trial_count": 7,
        "best_fit_trial": null,
        "best_urgency_trial": {
          "nct_id": "NCT06542250",
          "brief_title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",
          "overall_status": "RECRUITING",
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "last_update_posted": "2026-02-10"
        },
        "jobs": {
          "recent_window_days": 45,
          "spike_threshold": 2,
          "relevant_recent_jobs": 0
        },
        "reasons": {
          "fit_reason": "no trials",
          "urgency_reason": "trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",
          "urgency_source": "trial",
          "access_reason": "company on watchlist / ATS known"
        },
        "bonuses": {
          "recent_trial_bonus": 0.5,
          "multi_trial_bonus": 0.6,
          "any_recent_trial_update": true
        },
        "weights": {
          "fit": 1.0,
          "urgency": 1.0,
          "access": 1.0
        }
      }
    },
    {
      "company": "GSK",
      "total_score": 3.0,
      "fit_score": 1.0,
      "urgency_score": 0.0,
      "access_score": 2.0,
      "trigger_summary": "",
      "evidence_links": [],
      "target_roles": [
        "Director/VP, Translational Medicine (Oncology/Immunology)",
        "Head/Director, Clinical Biomarkers / Translational Biomarkers",
        "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
        "Director, Bioassay / Potency / Analytical Development",
        "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
      ],
      "trial_count": 0,
      "recent_job_hits": 0,
      "best_fit_trial_title": null,
      "best_fit_trial_status": null,
      "best_fit_trial_phases": null,
      "best_fit_trial_last_update": null,
      "fit_reason": "no trials",
      "urgency_reason": "no trials",
      "urgency_source": "trial",
      "access_reason": "company on watchlist / ATS known",
      "bonus_recent_trial": 0.0,
      "bonus_multi_trial": 0.0,
      "job_hit_titles": [],
      "job_hit_keywords": [],
      "score_details": {
        "trial_count": 0,
        "best_fit_trial": null,
        "best_urgency_trial": null,
        "jobs": {
          "recent_window_days": 45,
          "spike_threshold": 2,
          "relevant_recent_jobs": 0
        },
        "reasons": {
          "fit_reason": "no trials",
          "urgency_reason": "no trials",
          "urgency_source": "trial",
          "access_reason": "company on watchlist / ATS known"
        },
        "bonuses": {
          "recent_trial_bonus": 0.0,
          "multi_trial_bonus": 0.0,
          "any_recent_trial_update": false
        },
        "weights": {
          "fit": 1.0,
          "urgency": 1.0,
          "access": 1.0
        }
      }
    }
  ],
  "target_roles": [
    "Director/VP, Translational Medicine (Oncology/Immunology)",
    "Head/Director, Clinical Biomarkers / Translational Biomarkers",
    "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
    "Director, Bioassay / Potency / Analytical Development",
    "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
  ]
}